The condition of memory loss is termed as Alzheimer’s disease, affecting more than 5 million people and there is still no definite cure. A research team reported that an experimental drug could treat Alzheimer’s disease by slowing down the process of clear thinking and memory.

Dr. Lynn Kramer, the chief medical officer of the neurology division from Eisai drug said, “We had a 47 percent reduction in decline at 18 months”.

The findings were presented by Eisai and its U.S. partner Biogenat the Alzheimer’s Association annual meeting in Chicago on last Wednesday.

This monoclonal antibody drug named BAN2401was designed to remove amyloid plaques from the brain, which causes the disease. Kramer said, “This is the first large trial to support the amyloid hypothesis.” This drug could clear the plaques by 93 percent at the highest dose.

Dr. James Hendrix, the director of global science initiatives at the Alzheimer’s Association, said “Not only do we see a slowing in the rate of cognitive decline, we also see that reduction of amyloid burden in the brain as measured by amyloid PET (imaging); That biomarker confirmation really adds confidence that what you are seeing in the primary measure is real.”

The phase 3 clinical trial is still pending before seeking US-FDA approval. The Alzheimer's Association said, “The global urgency to better treat and prevent Alzheimer’s disease and other dementias is higher than ever, and growing." Hence anything that might help would be most welcome.